Health Sciences Authority has recalled
MEIJUMET Prolonged Release (PR) 750mg tablets, a brand of metformin medicine for diabetes.
Other brands of metformin medicines prescribed by SingHealth institutions are not affected.
-
There is no immediate health risk.
-
Do not stop Meijumet PR on your own, as stopping the medication may raise your blood sugar levels.
-
If you are taking
MEIJUMET Prolonged Release (PR) 750mg tablets, please come to exchange it for another brand at our PHARMACY in KK Women’s and Children’s Hospital (KKH) within the next 3 months.
Three metformin products have been found to contain trace amounts of a nitrosamine impurity, N-nitrosodimethylamine (NDMA), which are above the internationally acceptable level.
The potential risk of nitrosamines is associated with long-term use.
Health Sciences Authority (HSA) has tested all the metformin products in Singapore, and found that besides these three products, none of the other 43 metformin products contain NDMA above the acceptable level.
As such, there are adequate alternate metformin products (same strength and release profile) available. As a precautionary measure, HSA is conducting a consumer level recall of the three metformin products.
For more information on the recall, please refer to
HSA website here.